Summary

Overview
Global tretinoin market reached US$ XX million in 2022 and is expected to reach US$ XX million by 2030, growing at a CAGR of XX% during the forecast period 2023-2030.
Tretinoin, also known as all-trans retinoic acid, is a widely used medication for treating acne and acute promyelocytic leukemia. It is available in the form of cream, gel, or ointment for topical application for acne treatment, while it is taken orally for up to three months for leukemia treatment.
Market Dynamics: Drivers & Restraints
High Prevalence of Dermatological Conditions
The increasing prevalence of dermatological conditions, especially acne, is expected to drive the global market growth during the forecast period. For instance, according to Yale Medicine, adult women between the ages of 20 and 40 frequently visit dermatology clinics seeking treatment for acne. Clinical trial data suggests that around 50% of women in their 20s, 33% of women in their 30s, and 25% of women in their 40s suffer from acne. Additionally, the Global Burden Disease 2019 study reports that acne is the eighth-most prevalent disease worldwide, with a prevalence rate of 9.4%. Moreover, approximately 85% of young people aged 12-25 years are affected by acne vulgaris, and this trend is expected to continue in this population.
Side Effects
Although Tretinoin is an effective medication for treating acne and acute promyelocytic leukemia, it can cause side effects such as itching, excessive dryness, redness, and scaling. Moreover, the administration of Tretinoin for the treatment of leukemia can lead to retinoic acid syndrome, liver damage, hypertension, and other side effects, which can limit the global market's growth during the forecast period. Additionally, stringent regulatory guidelines and the availability of other treatment options are also expected to slow the market's growth during the forecast period.
Segment Analysis
The global tretinoin market is segmented based on strength, application, distribution channel and region.
Tretinoin 0.1% Strength Segment is Expected to Dominate Market
Owing to recent product approvals and launches, the Tretinoin 0.1% Strength is expected to dominate the global market during the forecast period. For instance, the FDA approved Twyneo (tretinoin 0.1% and benzoyl peroxide 3%) cream for the topical treatment of acne vulgaris in patients aged 9 years and older in July 2021. Moreover, Galderma launched TWYNEO (tretinoin and benzoyl peroxide) Cream, 0.1%/3% in March 2022 at the American Academy of Dermatology (AAD) Annual Meeting. TWYNEO Cream is the first and only 0.1% tretinoin and 3% benzoyl peroxide (BPO) 2-in-1 combination established to rapidly treat mild to intense facial acne.
Geographical Analysis
North America is Expected to Dominate the Global Market
North America is expected to hold the majority of the global market share during the forecast period due to the increasing number of individuals with acne in the region. For instance, according to the American Academy of Dermatology (AAD), over 50 million Americans are affected by acne conditions every year, and the administration of Tretinoin for the skin is the most effective treatment. Further, market developments in North America, such as the exclusive license contract for TWYNEO and EPSOLAY for the Canadian market between Sol-Gel Technologies, Ltd., an Israel-based dermatology firm, and Searchlight Pharma Inc., a private Canadian specialty pharmaceutical corporation, are expected to contribute to the regional market growth during the forecast period.
COVID-19 Impact Analysis
The COVID-19 outbreak was an unexpected health concern that significantly impacted the global Tretinoin market growth. Different regulatory bodies-imposed restrictions on socializing and social gatherings, which negatively impacted the global market. During the pandemic, the restriction on socializing and social gatherings resulted in a reduction in the demand for cosmetic products. However, the post pandemic the market is attaining its pre-pandemic levels.
Market Segmentation
By Strength
• 0.025%
• 0.01%
• 0.05%
• 0.1%
• Others
By Application
• Acne
• Acute Promyelocytic Leukemia (APL)
• Others
By Distribution Channel
• Hospitals & Clinics Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Key Developments
• In June 2021, Sol-Gel Technologies, Ltd., a clinical-stage dermatology corporation, and Galderma, the globe’s most extensive autonomous dermatology corporation, formed two exclusive 5-year license contracts for the commercialization of EPSOLAY and TWYNEO in the United States.
• In November 2022, Tretinoin Creams, UK-based pharmaceutical corporation extended its inventory with a new product range including Tretinoin Cream 0.05, Tretinoin Cream 0.1, and the lower strength Tretinoin Cream 0.025 version.
• In February 2022, Ro Derm launched a teledermatology service connecting consumers with a U.S. licensed healthcare expert to deliver a consultation and prescription medicine that is customized to suit the consumer’s requirements.
Competitive Landscape
The major global players in the market include BASF, LGM Pharma, Gyma Laboratories, MYLAN PHARMACEUTICALS INC., Glaxosmithkline Inc., Janssen Pharmaceuticals, Inc., Bausch Health Companies Inc., Ortho Dermatologics, Galderma and Searchlight Pharma Inc.
Why Purchase the Report?
• To visualize the global tretinoin market segmentation based on strength, application, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of tretinoin market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key product of all the major players.
The global tretinoin market report would provide approximately 61 tables, 60 figures and 182 pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

ページTOPに戻る

Table of Contents

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Strength
3.2. Snippet by Application
3.3. Snippet by Distribution Channel
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. High Prevalence of Dermatological Conditions
4.1.1.2. XX
4.1.2. Restraints
4.1.2.1. Side Effects
4.1.2.2. XX
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Pricing Analysis
5.3. Regulatory Analysis
5.4. Patent Analysis
5.5. Unmet Need
5.6. End-user Trend
5.7. SWOT Analysis
5.8. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Strength
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Strength
7.1.2. Market Attractiveness Index, By Strength
7.2. 0.1%*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. 0.025%
7.4. 0.01%
7.5. 0.05%
7.6. Others
8. By Application
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.1.2. Market Attractiveness Index, By Application
8.2. Acne*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Acute Promyelocytic Leukemia (APL)
8.4. Others
9. By Distribution Channel
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.1.2. Market Attractiveness Index, By Distribution Channel
9.2. Hospitals & Clinics Pharmacies*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.2.3. Retail Pharmacies
9.3. Online Pharmacies
9.4. Others
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Strength
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Strength
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Strength
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Strength
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Strength
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. BASF*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. LGM Pharma
12.3. Gyma Laboratories, Inc.
12.4. MYLAN PHARMACEUTICALS INC.
12.5. Glaxosmithkline Inc.
12.6. Janssen Pharmaceuticals, Inc.
12.7. Bausch Health Companies Inc.
12.8. Ortho Dermatologics
12.9. Galderma
12.10. Searchlight Pharma Inc.
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us